InvestSMART

Exopharm Limited (ASX: EX1) - Announcements

- Current share price for EX1 : $0.011

ASX company news and announcements for Exopharm Limited (EX1) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Exopharm Limited (EX1) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Exopharm Limited (EX1), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Exopharm Limited (EX1)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Notification regarding unquoted securities - EX1 9 Mar 2023 12:28PM $0.015 $0.011 fallen by 26.67%
- Notice under s708A(12C)(e) of the Corporations Act 2001(Cth) 9 Mar 2023 12:28PM $0.015 $0.011 fallen by 26.67%
- EX1 to Receive $1m from the Issue of Convertible Notes 9 Mar 2023 12:27PM $0.015 $0.011 fallen by 26.67%
- Trading Halt 9 Mar 2023 9:14AM $0.015 $0.011 fallen by 26.67%
- EX1 to Receive $0.431m in Prepayment of R&D Tax Incentive 9 Mar 2023 8:10AM $0.015 $0.011 fallen by 26.67%
- Appendix 4D and Half Year Report for period 31 December 2022 27 Feb 2023 8:05AM $0.015 $0.011 fallen by 26.67%
- Initial Director's Interest Notice - CB 22 Feb 2023 5:07PM $0.016 $0.011 fallen by 31.25%
- Final Director's Interest Notice - JK 22 Feb 2023 5:05PM $0.016 $0.011 fallen by 31.25%
- Board changes adds Australian capital markets expertise 22 Feb 2023 5:05PM $0.016 $0.011 fallen by 31.25%
- Ceasing to be a substantial holder 15 Feb 2023 4:10PM $0.015 $0.011 fallen by 26.67%
- Added Funding for 2023 13 Feb 2023 10:23AM $0.065 $0.011 fallen by 83.08%
- Trading Halt 9 Feb 2023 9:16AM $0.065 $0.011 fallen by 83.08%
- Quarterly Activities Report and Appendix 4C 31 Jan 2023 1:47PM $0.069 $0.011 fallen by 84.06%
- Notification of cessation of securities - EX1 20 Dec 2022 5:09PM $0.068 $0.011 fallen by 83.82%
- Final Director's Interest Notice 20 Dec 2022 5:05PM $0.068 $0.011 fallen by 83.82%
- Operations review, Board and other changes 20 Dec 2022 4:59PM $0.068 $0.011 fallen by 83.82%
- EX1 to Receive $0.96m in Prepayment of R&D Tax Incentive 25 Nov 2022 11:45AM $0.091 $0.011 fallen by 87.91%
- Constitution 24 Nov 2022 10:08AM $0.085 $0.011 fallen by 87.06%
- Results of Meeting 24 Nov 2022 10:07AM $0.085 $0.011 fallen by 87.06%
- Exosome manufacture taken to the next level 17 Nov 2022 8:21AM $0.082 $0.011 fallen by 86.59%
- EX1 will commence LEAP technology transfer to AIRM under MSA 14 Nov 2022 8:27AM $0.082 $0.011 fallen by 86.59%
- Upcoming Conference Presentation ANZSEV2022 8 Nov 2022 10:06AM $0.095 $0.011 fallen by 88.42%
- Quarterly Activities Report and Appendix 4C 31 Oct 2022 8:10AM $0.100 $0.011 fallen by 89%
- Upcoming Webinar 27 Oct 2022 3:46PM $0.100 $0.011 fallen by 89%
- Exopharm Received R&D Tax Incentive Refund 27 Oct 2022 8:12AM $0.105 $0.011 fallen by 89.52%

76 - 100 of 313 results

Page 4 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.